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Abstract  Background/Objective:  Concomitant  prescription  of  two  or  more  psychiatric  med-
ications has  become  the  rule  and  patients  could  adhere  differently  to  their  various
drugs prescribed.  Sidorkiewicz  et  al.  published  a  questionnaire  for  assessing  adherence
to each  specific  drug.  Method:  This  study  explored  the  predictive  validity  of  the  Span-
ish version  of  the  Sidorkiewicz  questionnaire  in  a  sample  of  470  consecutive  psychiatric
outpatients  using  897  psychiatric  drugs.  Results:  The  questionnaire  showed  adequate  pre-
dictive validity  in  both  univariate  and  multivariate  analyses  (logistic  regression  and  CHAID
segmentation)  since  they  demonstrated  a  significant  association  with  the  10-item  Drug
Attitude  Inventory  and  with  the  Necessity  and  Concern  Scales  of  the  Beliefs  about
Medications  Questionnaire.  Some  demographic  and  clinical  variables  were  significant  in
the univariate  analyses  but  lost  significance  in  the  multivariate  analyses.  Conclusions:
The adherence  of  the  psychiatric  patient  to  his/her  prescribed  treatment  may  not  be
significantly  influenced  by  socio-demographic  or  clinical  characteristics,  but  rather  by  atti-
tudes toward  medication,  perceptions  of  personal  necessity  for  medication,  and  concerns∗ Corresponding author: Departamento de Medicina Interna, Dermatología y Psiquiatría, Facultad de Medicina, Universidad de La Laguna,
38071 San Cristóbal de La Laguna, Tenerife, Spain.
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about  its  potential  adverse  effects.  This  study’s  findings  suggest  that  the  Spanish  version  of
the Sidorkiewicz  questionnaire  may  be  a  useful  and  valid  instrument  for  assessing  adherence  to
each individual  drug  taken  by  psychiatric  outpatients  undergoing  polypsychopharmacy.
© 2017  Asociación  Española  de  Psicoloǵıa  Conductual.  Published  by  Elsevier  España,  S.L.U.  This













Validez  predictiva  del  instrumento  de  Sidorkiewicz  en  español:  valorando  la
adherencia  a  cada  fármaco  individual
Resumen  Antecedentes/Objetivo:  La  prescripción  concomitante  más  de  un  psicofármaco  en
un mismo  paciente  se  ha  convertido  en  la  regla  de  la  práctica  clínica  psiquiátrica  actual,
pudiendo adherirse  los  pacientes  de  manera  diferente  a  sus  diversos  fármacos  prescritos.
Sidorkiewicz  y  colaboradores  publicaron  un  cuestionario  para  evaluar  la  adherencia  a  cada
fármaco tomado  por  el  paciente.  Método:  Este  estudio  valora  la  validez  predictiva  de  la  ver-
sión española  del  cuestionario  de  Sidorkiewicz  en  una  muestra  de  470  pacientes  ambulatorios
psiquiátricos  consecutivos  que  usaban  897  fármacos  psiquiátricos.  Resultados:  El  cuestionario
mostró una  adecuada  validez  predictiva,  tanto  en  análisis  univariados  como  multivariados
(regresión logística  y  CHAID),  registrándose  asociaciones  significativas  con  el  DAI-10  y  con  las
escalas de  Necesidad  y  Preocupación  del  BMQ.  Algunas  variables  sociodemográficas  y  clínicas
fueron significativas  en  el  análisis  univariado  perdiendo  su  significación  en  el  multivariado.
Conclusiones:  La  adherencia  del  paciente  psiquiátrico  al  tratamiento  no  está  condicionada  por
características  sociodemográficas  o  clínicas,  sino  por  actitudes  hacia  la  medicación  y  por  las
percepciones  de  necesidad  personal  de  la  medicación  y  preocupaciones  sobre  sus  posibles  efec-
tos adversos.  La  versión  española  del  cuestionario  de  Sidorkiewicz  es  un  instrumento  válido
para evaluar  la  adherencia  a  cada  fármaco  tomado  por  pacientes  psiquiátricos  ambulatorios
polimedicados.
© 2017  Asociación  Española  de  Psicoloǵıa  Conductual.  Publicado  por  Elsevier  España,  S.L.U.










































Polypharmacy,  taking  multiple  drugs,  is  becoming  com-
on  and  almost  the  norm  for  most  psychiatric  patients
Ghaemi,  2002).  The  popularity  of  polypharmacy  is  some-
hat  surprising  since  it  is  based  on  experience  rather  than
vidence  (Stahl,  2002)  and  there  is  general  agreement
hat  polypharmacy  can  interfere  with  optimal  medication
dherence  (Murray  &  Kroenke,  2001)  which  may  lead  to
imited  treatment  effectiveness  and  result  in  higher  rates  of
elapse,  hospitalization,  and  disability  (Sajatovic,  Velligan,
eiden,  Valenstein,  &  Ogedegbe,  2010).  The  prevalence
f  polypharmacy  in  psychiatry  varies  by  country  and  even
ithin  different  mental  health  resources  in  one  country
nd  can  also  be  influenced  by  differing  definitions.  Having
efined  polypharmacy  as  the  use  of  two  or  more  psychoac-
ive  medications  to  treat  the  same  psychiatric  condition
Kingsbury,  Yi,  &  Simpson,  2001),  in  our  catchment  area
n  the  Canary  Islands,  Spain,  we  found  a  42%  prevalence
n  a  large  sample  of  >2,500  psychiatric  outpatients  repre-
enting  the  population  of  the  Community  Mental  Health
enters  (with  a  mean  number  of  different  psychotropic
rugs  =  1.63  ±0.93,  range  1--7)  (De  las  Cuevas  &  Sanz,
004).  Strikingly,  the  prevalence  increases  to  93%  in  >1,300




ommunity  Mental  Health  Centers  (3.3  ±  1.3,  range,  1--9)
De  las  Cuevas  &  Sanz,  2005).
There  is  no  established  gold  standard  method  for  mea-
uring  medication  adherence;  each  method  has  pros  and
ons  (Garfield,  Clifford,  Eliasson,  Barber,  &  Willson,  2011;
illiams,  Amico,  Bova,  &  Womack,  2013).  Although  self-
eports  tend  to  overestimate  adherence  behavior  (Osterberg
 Blaschke,  2005),  the  use  of  validated  self-report  ques-
ionnaires  is  the  simplest  and  least  expensive  method  of
easuring  adherence  (Garfield  et  al.,  2011;  National  Col-
aborating  Centre  for  Primary  Care,  NICE,  2009).  Moreover,
elf-report  questionnaires  provide  actionable  information  to
edical  providers  about  patient  medication-taking  behavior
Stirratt  et  al.,  2015) in  clinical  psychiatric  settings.
In  situations  of  polypharmacy,  available  self-report  ques-
ionnaires  for  assessing  medication  adherence  are  hampered
ecause  they  provide  a  measure  of  global  adherence  in
ach  patient,  but  do  not  provide  information  about  each
ndividual  drug  taken  by  each  patient.  In  our  experi-
nce,  this  is  a  major  problem,  because  our  psychiatric
atients  appear  to  adhere  differently  to  the  various  psy-
hiatric  medications  prescribed  to  them  and  exhibit  diverse






















































Predictive  validity  of  the  Sidorkiewicz  in  Spanish  
experience  is  supported  by  the  limited  available  information
on  medication  adherence  studies  in  non-psychiatric  patients
(Osterberg,  Urquhart,  &  Blaschke,  2010;  Viana  et  al.,
2014).
The  idea  of  having  a  global  measure  of  medication  adher-
ence  for  each  patient  basically  implies  that  adherence  is  a
characteristic  of  each  patient  influenced  by  the  complexity
of  the  prescription  regimen,  long-term  medication  use,  and
clinical  conditions.  On  the  other  hand,  Sidorkiewicz,  Tran,
Cousyn,  Perrodeau  and  Ravaud  (2016),  proposed  an  original
and  new  approach  based  on  the  idea  that  adherence  also
is  a  property  of  medicine  classes.  This  self-reported  adher-
ence  tool  is  an  instrument  for  assessing  adherence  for  each
individual  drug  in  patients  with  long-term  therapies.  The
questionnaire  contains  five  questions  related  to  (1)  early  dis-
continuation  of  the  drug,  (2)  systematic  omission  of  a daily
dose  (e.g.,  at  noon),  (3)  drug  holidays,  (4)  skipping  doses
and  (5)  schedule  errors.  Each  question  has  two  or  three
possible  answers,  and  the  language  uses  non-threatening
sentences  to  reduce  social  desirability  bias,  with  practical
examples  and  pictographs  to  help  patients  recognize  their
medicine-taking  behaviors.  The  instrument  defines  six  drug
adherence  levels  for  a  given  drug.  Level  1  corresponds  to
high  drug  adherence  (no  drug  holidays,  no  missing  doses  and
no  schedule  errors);  level  2  corresponds  to  good  drug  adher-
ence  (no  drug  holidays  and  no  missing  doses;  schedule  errors
≥4  h);  level  3  corresponds  to  moderate  drug  adherence  (no
drug  holidays;  missing  doses  once  or  twice  a  month  and/or
schedule  errors  ≥12  h);  level  4  corresponds  to  poor  drug
adherence  (drug  holidays  for  2--3  days  and/or  missing  doses
≥1/week);  level  5  corresponds  to  very  poor  drug  adherence
(systematically  skipping  a  daily  dose  and/or  drug  holidays  ≥6
days);  and  level  6  corresponds  to  drug  discontinuation.  The
authors  (Sidorkiewicz  et  al.,  2016)  report  adequate  psycho-
metric  properties,  including  good  convergent  validity  with
the  Morisky  Medication  Adherence  Scale  of  4  items  (Morisky,
Green,  &  Levine,  1986),  with  the  Lu  self-reported  adherence
instrument  (Lu  et  al.,  2008),  and  a  significant  agreement
with  the  adherence  evaluated  by  their  physicians.  It  also
showed  good  temporal  stability  (test-retest).
This  new  tool  appears  to  us  to  be  the  most  effective
method  for  measuring  treatment  using  self-reported  adher-
ence,  which  is  our  major  priority  for  psychiatric  clinical
practice,  and  for  advancing  our  research  studies  in  medi-
cation  adherence  in  psychiatry.  This  study  aims  to  explore
the  predictive  validity  of  the  Spanish  version  of  the  recently
published  Sidorkiewicz  adherence  tool  in  a  psychiatric  out-
patient  setting.  Thus,  it  is  our  first  attempt  to  explore  the
different  medication-taking  behaviors  for  each  drug  taken
by  patients  with  polypharmacy  in  our  outpatient  catchment
area.
Method
Study  design  and  participants
This  cross-sectional  study  was  completed  at  the  Commu-
nity  Mental  Health  Services  of  a  university  hospital  in  the
Canary  Islands,  Spain.  The  inclusion  criteria  for  the  psychi-
atric  outpatients  were  as  follows:  (1)  18  years  or  older,  (2)






 psychiatric  disorder;  (4)  treated  for  at  least  3 months
ith  psychiatric  drugs,  and  (5)  participating  voluntarily.
ach  participant  received  a  full  explanation  of  the  study,
fter  which,  all  participants  signed  an  informed  consent
ocument.  This  study  was  approved  by  the  Ethics  Commit-
ee  for  Clinical  Research  of  the  University  Hospital  Nuestra
eñora  de  la  Candelaria,  in  the  Canary  Islands.  Each  partic-
pant  then  filled  out  a  brief  socio-demographic  survey  and
he  rest  of  the  questionnaires.  We  offered  no  reward  for
articipation.
A  final  sample  of  470  consecutive  psychiatric  outpatients
as  accepted  for  participation  in  this  study  (560  patients
nvited  to  participate,  84%  response  rate).  Table  1  shows
heir  socio-demographic  and  clinical  variables.
nstruments
idorkiewicz  instrument  translation.  The  guidelines  for
ross-cultural  adaptation  of  self-report  measures  developed
y  Beaton,  Bombardier,  Guillemin,  and  Ferraz  (2000), were
sed  for  this  five-stage  translation.  In  the  first  stage,  the
nitial  translation,  two  independent  bilingual  translators,
oth  competent  in  English  and  Spanish  and  one  of  them
ware  of  the  concepts  being  examined  in  the  questionnaire
eing  translated,  whose  mother  tongue  is  the  target  lan-
uage  (Spanish),  translated  the  original  questionnaire  from
nglish  to  Spanish.  In  the  second  step,  synthesis  of  the
ranslations,  the  translators  reached  a  consensus  on  the
ranslation  of  words,  phrases  and  items  based  on  the  synthe-
is  of  translations,  working  from  the  original  questionnaire,
s  well  as  the  versions  of  the  first  and  second  translators.
he  third  stage,  the  back  translation,  involving  a  new  bilin-
ual  translator  who  was  totally  blind  to  the  original  version,
ranslated  the  Spanish  version  of  the  questionnaire  back
nto  the  original  English  language  as  a  process  of  validity
hecking  to  make  sure  that  the  translated  version  reflected
he  same  item  content  as  the  original  version.  The  fourth
tage,  the  expert  committee  phase,  analyzed  the  cultural
uitability  and  content  validity  testing;  it  was  conducted
y  three  independent  psychiatrists  and  psychologists.  These
rofessionals  rated  the  degree  to  which  each  item  of  the
nstrument  covered  the  content  that  was  supposed  to  be
easured  as  an  index  of  representativeness  and  content
alidity.  They  also  evaluated  the  comprehension  and  equiv-
lence  of  translation  (semantic  equivalence  and  content)
etween  the  English  and  Spanish  versions.  The  final  stage  of
he  adaptation  process,  stage  five,  the  test  of  the  final  ver-
ion,  was  the  field  test  of  the  new  questionnaire.  It  sought  to
se  the  prefinal  version  with  30  patients  from  the  target  set-
ing.  These  patients  completed  the  questionnaire,  and  were
nterviewed  to  probe  what  they  thought  was  meant  by  each
uestionnaire  item  and  the  chosen  response.  Both  the  mean-
ng  of  the  items  and  responses  were  explored,  examining  the
istribution  of  responses.  Appendix.
To  explore  the  predictive  validity  (Nunnally  &  Bernstein,
994) of  the  Sidorkiewicz  instrument  two  scales  were  used:
he  10-item  Drug  Attitude  Inventory  and  the  Beliefs  about
edication  Questionnaire  Specific  Scale.  These  two  scales
ere  chosen  due  to  (1)  our  ample  experience  with  them,
2)  their  consistency  in  predicting  adherence  to  prescribed
reatment  in  psychiatric  care,  (3)  their  ability  to  be  used
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Table  1  Socio-demographic  and  clinical  characteristics  of  psychiatric  outpatients  (n  =  470,  using  897  psychoactive  drugs).
Variable Mean 95%  CI Median SD Range Skewness Kurtosis KS  test  p  value
Lower  Upper
Age  (years)  45.75  44.54  46.96  46.50  13.34  18  /  87  0.07  -0.43  .506
Treatment  time  (months) 86.28  77.71  94.85  48.00  94.56  1  /  480  1.59  2.42  .000**
No.  of  admissions 0.78  0.61  0.96  0.00  1.93  0  /  20  4.83  32.78  .000**
No.  of  drugs  used 1.92  1.81  2.02  1.00  1.17  1  /  6  1.30  1.18  .000**
DAI-10  2.69  2.43  2.94  4.00  3.90  -10  /  10  -0.44  -0.20  .000**
BMQ-Necessity  3.47  3.40  3.54  3.60  1.04  1  /  5  -0.43  -0.55  .000**
BMQ-Concern  2.80  2.73  2.87  3.00  1.07  1  /  5  -0.18  -1.00  .000**
Variable Category Frequency Percent 95%  CI
Lower  Upper
Sex  Male  223  47.4%  42.9%  52.1%
Female 247  52.6%  47.9%  57.1%
Educational  level  Can  read  and  write  12  2.6%  1.3%  4.4%
Primary school  132  28.1%  24.1%  32.4%
Secondary  school  195  41.5%  37.0%  46.1%
College or  higher  131  27.9%  23.9%  32.2%
Involuntary  admissions  Yes  91  19.4%  15.9%  23.2%
No 379  80.6%  76.8%  84.1%
Diagnoses Depressive  disorder  179  38.1%  33.7%  42.6%
Anxiety disorder  130  27.7%  23.7%  32.0%
Schizophrenia  110  23.4%  19.6%  27.5%
Bipolar disorder  33  7.0%  4.9%  9.7%
Personality  disorder  14  3.0%  1.6%  4.9%
Other diagnoses  4  0.9%  —  —
Psychoactive  drug  Antidepressants  194  41.3%  36.8%  45.9%
Anxiolytics  126  26.8%  22.9%  31.1%
Antipsychotics  111  23.6%  19.8%  27.7%
Mood stabilizers  39  8.3%  6.0%  11.2%
Polypharmacy  Monotherapy  236  50.2%  45.6%  54.8%
Polypharmacy 234  49.8%  45.2%  54.4%



































** p < .01; the variable does not adjust to normality.
n  any  treatment  context,  and  (4)  their  brevity,  in  order  to
inimize  the  burden  for  psychiatric  patients  who  may  be
ognitively  impaired.
Drug  Attitude  Inventory--10  items  (DAI-10).  The  DAI-
0  was  created  to  measure  attitudes  toward  psychiatric
edications  in  adults  (Hogan,  Awad,  &  Eastwood,  1983).
t  is  a  self-report  questionnaire  consisting  of  true/false
tatements  about  the  perceived  effects  and  benefits  of
sychiatric  drugs  with  which  the  patients  can  agree  or
isagree.  The  scoring  equals  the  total  sum  of  the  items,
anging  from  −  10  (very  poor  attitude)  to  +  10  (best  possible
ttitude).  DAI-10  scores  predicted  adherence  in  different
sychiatric  disorders  (De  las  Cuevas,  de  Leon,  Peñate,  &
etancort,  2017;  De  las  Cuevas  &  Peñate,  2015a);  it  has  been
sed  as  a  validation  standard  for  other  scales  (Chen,  Tam,
ong,  Law,  &  Chiu,  2005;  Jeste  et  al.,  2003).  In  our  study  we
sed  the  validated  Spanish  version  of  the  scale  (Cronbach’s
lpha:  .67).
Beliefs  about  Medication  Questionnaire.  The  BMQ-
pecific  (De  las  Cuevas  et  al.,  2011;  Horne  &  Weinman,




s  prescribed  for  a  specific  illness,  examining  perceptions
f  personal  necessity  for  medication  and  concerns  about
otential  adverse  effects.  The  scale  includes  10  items  in  two
ubscales:  Concern  and  Necessity,  each  with  five  items.  The
egree  of  agreement  with  each  statement  is  indicated  on
 five-point  Likert  scale,  ranging  from  1  =  strongly  disagree
o  5  = strongly  agree. The  Necessity/Concern  framework  has
roven  to  be  a  useful  conceptual  model  for  understanding
atients’  perspectives  on  prescribed  medicines  and  a  funda-
ental  factor  in  predicting  their  adherence  to  treatment  (De
as  Cuevas,  Peñate,  &  Cabrera,  2016a;  Horne  et  al.,  2013).  In
ur  study  we  used  the  validated  Spanish  version  of  the  scale
Necessity  subscale  Cronbach’s  alpha:  .70;  Concern  subscale
ronbach’s  alfa:  .80).
ata  analysishe  data  were  analyzed  using  SPSS  version  22.2  for  win-
ows  (IBM  Corp.  Released,  2013).  Techniques  and  statistical
ests  used  included:  distribution  of  frequencies  and  per-
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Table  2  Descriptive  analysis.  Adherence  to  psychotropic  drugs  (N  =  897).
n Percentage 95%  CI
Variable  Category  Lower  Upper
Level  of  adherence  High  (1)  393  43.8%  40.5%  47.1%
Good (2) 75  8.4%  6.6%  10.4%
Moderate  (3) 121  13.5%  11.3%  15.9%
Poor (4)  111  12.4%  10.3%  14.7%
Very Poor  (5)  58  6.5%  4.9%  8.3%
Discontinuation  (6)  139  15.5%  13.2%  18.0%




































No (4-6)  
centages  for  qualitative  variables;  data  exploration  with
normal-fit  QQ  graph,  histogram,  asymmetry  coefficients
and  kurtosis/height  together  with  the  Kolmogorov-Smirnov
goodness-of-fit  test  and  description  with  the  usual  centrality
(mean,  median)  and  variability  (standard  deviation,  range:
Min/Max  and  interquartile  range)  for  quantitative  variables;
and  tests  of  difference  of  means  (student’s  t  and  ANOVA)
next  to  its  non-parametric  alternatives  (Mann-Whitney  and
Kruskall-Wallis),  Chi-square,  ROC  Curve,  Binary  Logistic
Regression  and  CHAID  Segmentation  Tree  for  inferential
analysis.  For  some  analyses,  original  levels  of  adherence
supplied  by  the  tool  were  dichotomized  into  ‘‘adherent’’
(which  included  previous  high  (1),  good  (2),  and  moderate
(3)  levels)  versus  ‘‘non-adherent’’  (which  included  previ-
ous  poor  (4),  very  poor  (5),  and  discontinuation  (6)  levels).
The  usual  confidence  level  of  5%  (significant  if  p  <  .050)  was
already  set,  except  for  the  Kolmogorov-Smirnov  normality
test,  which  was  considered  to  be  a  mismatch  only  if  p  <  .010
(1%).
Statistical  comments  on  differences  between  subjects
and  drugs.  This  study  recruited  a  sample  of  470  different
patients.  In  each  patient,  we  collected  data  regarding  the
adherence  to  one  or  more  drugs  prescribed  (not  always  the
same),  providing  a  total  of  897  drug  records  that  we  must
consider  as  independent  data  since  the  answers  given  by  a
patient  about  a  drug  do  not  depend  on  the  answers  given  by
the  same  patient  about  another  drug.  These  897  records  are
considered  to  be  a  valid  sample  size  for  the  analyses  to  be
performed.
Studying  predictive  validity.  According  to  Nunnally  and
Bernstein  (1994),  predictive  validity  is  ‘‘using  an  instrument
to  estimate  some  criterion  behavior  that  is  external  to  the
measuring  instrument  itself’’.  In  this  study,  we  use  3  exter-
nal  validators:  attitudes  toward  psychiatric  treatment,  and
beliefs  about  necessity  and  concern  of  prescribed  psychi-
atric  treatment  to  explore  the  predictive  validity  of  the
Spanish  version  of  the  Sidorkiewicz  adherence  instrument.
An  additional  proof  of  predictive  validity  would  be  that
demographic  and  clinical  variables  are  not  strong  predic-
tors  of  the  scores  on  the  Sidorkiewicz  adherence  instrument,
unless  their  influence  is  mediated  by  the  3  external  val-
idators.  To  test  this  additional  proof  of  predictive  validity,
we  hypothesize  that  any  significant  socio-demographic  or
clinical  variable  in  the  univariate  analyses  will  lose  its  sig-
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esults
ample  description
rom  April  to  June  2017,  470  consecutive  psychiatric
utpatients  were  recruited.  Table  1  describes  their  socio-
emographic  variables  including  a  mean  age  of  45.7;
pproximately  52%  were  women,  42%  completed  secondary
chool,  and  28%  had  a  university  degree.  The  most  important
ain  diagnoses  were  schizophrenia,  23%;  bipolar  disor-
er,  7%;  depressive  disorders,  38%;  anxiety  disorders,  27%;
nd  personality  disorders,  3%.  Patients  took  a  total  of  897
edications;  the  most  important  classes  were  antidepres-
ants  in  35%  of  patients,  antianxiety  benzodiazepines  in
5%,  antipsychotics  in  20%,  and  mood  stabilizers  in  11%
Table  1).  The  mean  treatment  duration  was  86  months  and
he  mean  number  of  different  psychoactive  drugs  prescribed
er  patient  was  1.9.  The  rate  of  polypharmacy  was  50%,
hich  includes  25%  of  patients  receiving  two  drugs,  14%
eceiving  three,  7%  receiving  four,  and  4%  of  the  patients
eceiving  five  or  more  psychotropic  drugs.
esults  from  the  Sidorkiewicz  adherence
nstrument
lobal  self-reported  adherence,  based  on  percentage,
ccording  to  the  Sidorkiewicz  adherence  tool  at  the  drug
evel  of  the  897  drugs,  disregarding  who  took  them,  was  high
n  44%,  good  in  8%,  moderate  in  13%,  poor  in  12%,  very  poor
n  7%  and  discontinued  the  drug  in  16%  (Table  2).  More  than
 third  of  polypharmacy  patients  reported  discordance  in
dherence  to  their  prescribed  treatment  (i.e.,  varying  lev-
ls  of  adherence  among  the  different  psychoactive  drugs
sed).
nivariate  analysis  of  socio-demographic  and
linical variables
o  explore  external  evidences  of  validity,  the  adherence  tool
as  used  to  compare  results  according  to  the  patients’  socio-
emographic  variables,  such  as  age,  gender,  and  educational
evel,  as  well  as  according  to  clinical  variables,  such  as  psy-
hiatric  diagnosis,  type  of  psychiatric  drug  used,  treatment
uration,  and  treatment  complexity  (polypharmacy).
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Table  3  Inferential  analysis.  Univariate  association  between  adherence,  attitudes  toward  psychiatric  treatment  and  beliefs
about necessity  and  concern  of  prescribed  psychiatric  treatment.
Variable Category DAI-10  Parametric  test  Non-parametric  test
n  Mean  (SD)  Median  Value  p  Value  p
Level  of  adherence  High  393  2.98  (3.53)  4.00 9.61 .000** 37.01 .000**
Good  75  3.87  (3.68)  4.00
Moderate  120  3.85  (3.40)  4.00
Poor  111  1.57  (4.44)  2.00
Very  poor 58  1.21  (3.98)  1.00
Discontinuation  139  1.73  (4.30) 2.00
Adherence  Yes 588  3.27  (3.54) 4.00 6.34 .000** 5.49 .000**
No  308  1.57  (4.28) 2.00
Variable Category BMQ-Necessity  Parametric  test  Non-parametric  test
n  Mean  (SD)  Median  Value  p  Value  p
Level  of  adherence  High  393  3.63  (0.99)  3.60 9.76 .000** 40.66  .000**
Good 75  3.78  (1.00)  4.00
Moderate  120  3.52  (0.94)  3.60
Poor 111  3.16  (1.03)  3.40
Very poor  58  3.30  (1.01)  3.40
Discontinuation  139  3.10  (1.15)  3.20
Adherence  Yes  589  3.63  (0.98)  3.80 6.65 .000** 6.03 .000**
No  308  3.15  (1.08)  3.40
Variable Category BMQ-Concern  Parametric  test  Non-parametric  test
n  Mean  (SD)  Median  Value  p  Value  p
Level  of  adherence  High  393  2.68  (1.05)  2.80 5.37 .000** 28.50 .000**
Good  75  2.61  (0.99)  2.80
Moderate  120  2.66  (1.05)  2.60
Poor 111  3.01  (0.98)  3.20
Very poor  58  3.03  (1.11)  3.20
Discontinuation  139  3.08  (1.17)  3.40
Adherence  Yes  589  2.66  (1.04)  2.80 5.14 .000** 5.28 .000**
No  308  3.05  (1.09)  3.40































** p < .01).
Although  women  self-reported  a  higher  adherence  (67.4%
s.  63.8%),  no  differences  were  obtained  in  the  level  of
dherence  as  a  function  of  gender  (X2 =  5.97,  p  =  .309;  r  =  .08)
r  dichotomized  adherence  (X2 =  1.29,  p  =  .256;  r  =  .03).
owever,  a  statistically  significant  correlation  was  found
etween  the  adherence  tool  and  age  (F  (5,  891)  =  2.29,
 =  .000):  self-reported  adherence  increased  with  patient
ge.  The  ROC  analysis  performed  to  find  the  cut-off  point
hat  maximizes  this  relationship  between  adherence  and  age
onfirmed  the  significant  relationship  (curve  area:  .56;  95%
C:  .52-  .60)  and  was  suggestive  of  the  age  of  65  years,  from
hich  there  is  a  greater  probability  of  adherence.  Concern-
ng  educational  level,  patients  with  lower  educational  level
eported  greater  adherence  (X2 =  9.40,  p  =  .024;  r  =  .19).
In  relation  to  patient  diagnosis,  the  adherence  tool
as  able  to  differentiate  between  the  five  major  groups
f  psychiatric  disorders  considered  (i.e.,  schizophrenia,
ipolar  disorders,  depressive  disorders,  anxiety  disorders,




 = .001;  r  =  .27);  dichotomized  adherence,  X2 =  25.97,
 = .001;  r  =  .17).  Patients  with  bipolar  disorder  self-reported
he  highest  adherence  (72.7%)  while  patients  with  per-
onality  disorder  the  lowest  one  (22.2%).  No  significant
orrelations  were  found  as  a  function  of  treatment  com-
lexity  (i.e.,  the  presence  of  polypharmacy;  level  of
dherence,  X2 =  4.94,  p  =  .423;  r  =  .07);  dichotomized  adher-
nce  (X2 =  0.42,  p  =  .519;  r  =  .02),  type  of  psychiatric  drug
sed  (level  of  adherence,  X2 =  24.50,  p  =  .057;  r  =  .16);
ichotomized  adherence  (X2 =  6.87,  p  =  .076;  r  =  .07)  or
reatment  duration  (F  =  0.05,  p  =  .819).
redictive  validity  using  three  external  validators
n univariate  analysesable  3  shows  the  associations  between  adherence,  atti-
udes  toward  psychiatric  treatment  and  beliefs  about
ecessity  for  and  concern  about  prescribed  psychiatric
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Table  4  Multiple  logistic  regression  model.  Predictive  factors  of  adherence  =  Yes  (N  =  896).
Factors  included  B  ET  (B)  Wald  P-sig  OR  95%  CI  of  OR
BMQ-Necessity  (per  unit  of  increase)  0.34  0.05  42.22  .000** 1.40  1.27/1.56
BMQ-Concern  (per  unit  of  decrease)  -0.24  0.06  19.36  .000** 1.27  1.14/1.41
DAI-10 (per  unit  of  increase)  0.07  0.02  11.66  .000** 1.07  1.03/1.11
Population  constant  -0.08  0.34  0.06  .811  -  -
Table  5  Summary  of  first  CHAD  tree  segmentation  with  7
terminal  nodes.
Node Adherence Characteristics
Concern  Attitudes  Necessity
7  91.2%  3.2-4.0  >4.4
10 90.7%  <3.2  >4.0  >4.8
9 74.3%  <3.2  >4.0  2.0-4.8
6 58.7%  3.2-4.0  ≤4.4




























** p < .01).
treatment.  Concerning  patients’  attitudes  toward  their
psychiatric  treatment,  both  in  contrast  to  the  level  of  adher-
ence  and  in  dichotomous  adherence,  a  highly  significant
relationship  (p  <  .001)  (Table  3)  was  found  such  that,  with-
out  doubt,  the  cases  with  higher  adherence  present  higher
scores  on  the  Drug  Attitudes  Inventory  (3.27  vs.  1.57;  differ-
ence  close  to  2  points).  Similar  highly  significant  associations
were  evidenced  between  adherence  and  the  perception  of
necessity  for  a  specific  psychiatric  drug  (BMQ-Necessity)  and
the  concern  about  its  adverse  consequences  (BMQ-Concern).
Predictive  validity  using  three  external  validators
in multivariate  analyses
After  these  results  and  considering  adherence  in  its  dichoto-
mous  form  as  the  main  variable  in  the  analysis,  we
proceeded  to  a  multivariate  study  of  these  three  varia-
bles  using  the  binary  logistic  regression  method.  The  results
of  this  method  are  summarized  in  Table  4. The  regression
model  presented  is  highly  significant  (p  <  .001  in  the  Omnibus
Test),  reaching  a  moderately  high  degree  of  adjustment
(22.1%,  according  to  Nagelkerke  R2)  and  correctly  classifying
93.5%  of  the  cases  with  adherence  and  69.3%  of  the  total.
Therefore,  the  model  is  very  effective  in  predicting  adher-
ence,  but  not  so  much  for  the  prediction  of  non-adherence
to  prescribed  treatment.  From  this  multivariate  perspec-
tive,  the  necessity  scale  is  revealed  as  the  main  factor  (p
<  .001)  for  adherence  prediction  (OR  =  1.40  per  unit  increase
in  need)  followed  by  the  concern  scale  (p  <  .001;  OR  =  1.27
per  unit  of  reduction  on  this  scale)  and  the  attitudes  scale  (p
<  .001;  OR  =  1.07  per  unit  of  increase).  Therefore,  the  three
scales  are  associated  in  multivariate  form  with  adherence,
demonstrating  their  relationship  with  it.  The  inclusion  of
interactions  between  these  three  factors  in  the  multivariate
model  did  not  add  significance  (p  >  .05).
Finally,  a  Chi-square  automatic  interaction  detection
(CHAID)  analysis  was  carried  out  to  explain  the  patients’
responses  to  the  categorical  dependent  variable  (adher-
ence:  yes/no)  in  reference  to  the  following  variables:
attitudes  toward  psychiatric  treatment,  perceived  necessity
of  the  medication  and  concerns  about  having  to  take  it.  The
results  of  this  tree  classification  method  (see  Supplementary
Material)  showed  that  the  profile  with  the  highest  degree  of
adherence  observed  is  the  correspondence  of  patients  with
average  values  on  the  concern  scale  and  high  values  on  the
necessity  scale,  regardless  of  their  attitudes  (91%).  It  follows
the  profile  of  cases  with  low  values  on  the  concern  scale
and  neutral  or  positive  values  in  attitudes  toward  medica-
tion,  regardless  of  their  perceived  degree  of  necessity  of





3 40.2%  >4.0
4  29.6%  <3.2  ≤4.4
egree  of  adherence  (30%)  was  found  in  those  patients  with
ow  values  on  the  concern  scale  and  negative  values  (≤4)
n  the  attitudes  scale.  As  reader  may  have  not  be  familiar
ith  the  interpretation  of  CHAID  tree  analyses,  Table  5  pro-
ides  a summary  of  the  7  terminal  nodes  order  according  to
ercentage  of  adherence.
redictive  validity  demonstrated  by  three  external
alidators eliminating  the  significance  of
ocio-demographic  and  clinical  variables  in
ultivariate analyses
ome  of  the  socio-demographic  and  clinical  variables,
ncluding  age  and  some  diagnoses,  were  significantly  associ-
ted  with  the  Sidorkiewicz  adherence  tool  in  the  univariate
nalyses.  None  of  these  variables  retained  significance  when
he  3  external  validators  were  introduced  in  the  multivari-
te  analyses,  the  logistic  regression  or  the  CHAID  analysis.
hus,  the  socio-demographic  and  clinical  variables  of  the
atient  seem  not  to  have  major  relevance  in  adherence  to
reatment.  Their  effects  in  the  univariate  analyses  appear
o  mainly  reflect  the  patients’  attitudes  towards  their  psy-
hiatric  medication,  their  perception  of  the  need  to  have  to
se  this  medication  and  their  concern  for  its  possible  side
ffects.
iscussion
o  our  knowledge,  this  is  the  first  study  that  assesses  the
sychometric  properties  of  the  Sidorkiewicz  adherence  tool
or  each  individual  drug  taken  by  psychiatric  patients.  The
riginal  instrument  was  tested  on  a  sample  of  consecu-
ive  patients  in  six  general  practice  outpatient  clinics  and
ix  academic  general  hospitals  in  France,  and  it  was  found












































































dherence  for  each  drug  taken  by  patients,  confirming  its
sability  in  hospital  and  primary  care  settings  (Sidorkiewicz
t  al.,  2016).
Medicine-taking  is  a  complex  human  behavior  and
atients  evaluate  medicines,  and  the  risks  and  benefits  of
edicines  using  the  resources  available  to  them  (Nunes
t  al.,  2009).  The  Necessity/Concern  framework  has  demon-
trated  its  utility  in  explaining  non-adherence  to  prescribed
edication  (De  las  Cuevas  et  al.,  2016a;  Maidment,  Liv-
ngston,  &  Katona,  2002)  and  shown  that  adherence  in
ong-term  conditions  for  psychiatric  disorders  is  associated
ith  stronger  perceptions  of  necessity  for  drug  treatment
nd  fewer  concerns  about  its  adverse  consequences  (Horne
t  al.,  2013).
Our  results,  both  from  the  univariate  and  the  multivariate
erspectives  (with  logistic  regression  and  CHAID  segmenta-
ion  analysis),  support  the  significant  relationships  of  this
dherence  tool  with  respect  to  factors  such  as  attitudes
oward  psychiatric  drug  treatment,  perceived  necessity  of
se  and  concern  about  its  adverse  consequences.  We  con-
ider  that  the  adherence  estimates  evaluated  by  this  tool  at
he  drug  level  may  be  more  accurate  than  those  obtained
ith  other  instruments  since  the  tool  does  not  make  value
udgments  about  whether  a  patient  is  adherent  or  not,  but
ather  evaluates  specific  behaviors  for  specific  drugs  with  a
‘no-blame  approach’’  approach,  which  would  avoid  social
esirability  by  suggesting  to  the  patient  that  non-adherence
an  be  habitual  and  certainly  his/her  decision  to  respect.
he  high  response  rate  obtained  in  our  study  supports  this
onsideration  and  suggests  good  acceptability  of  the  instru-
ent.
The  results  obtained  in  this  study  are  in  line  with  the
revious  work  of  our  research  group,  which  emphasized  the
ole  played  by  the  variables  of  the  health  belief  model  in
dherence  to  the  prescribed  psychiatric  treatment  (De  las
uevas  &  de  Leon,  2017;  De  las  Cuevas  et  al.,  2017;  De  las
uevas  et  al.,  2016a;  De  las  Cuevas  &  Peñate,  2015a;  De  las
uevas,  Peñate,  &  Cabrera,  2016b;  De  Leon  &  de  las  Cuevas,
017),  although  our  prior  research  is  limited  because  we
sed  the  Morisky  Medication  Adherence  Scale  of  8  items  as  an
nstrument  for  assessing  adherence  (De  las  Cuevas  &  Peñate,
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llowing  the  evaluation  of  each  patient’s  psychoactive  drug,
as  helped  us  to  further  establish  evidence  that  socio-
emographic  and  clinical  variables  of  the  patient  may  have
o  important  role  in  adherence,  while  the  patient’s  atti-
udes  and  beliefs  toward  his/her  medication  may  have  a  very
trong  role.  The  patient’s  preference  (Cooper  &  Norcross,
016)  and  self-motivation  (Marín-Navarrete  et  al.,  2017)  can
elp  to  select  the  best  treatment  (Beutler,  Someah,  Kim-
ara,  &  Miller,  2016)  for  each  patient  and  contribute  to
mprove  adherence.
This  study  has  focused  on  drug  treatment  adherence  at
he  drug  level.  It  remains  to  be  established  how  to  define
dherence  at  the  patient  level  when  the  patient  shows
ifferent  degrees  of  adherence  to  various  prescribed  psy-
hotropic  drugs.  The  authors  of  the  original  tool  defined
dherence  at  the  patient  level  as  ‘‘the  adherence  level  for
he  drug  for  which  the  patient  was  the  most  non-adherent’’
Sidorkiewicz  et  al.,  2016).  However,  we  believe  that  this
spect  of  adherence  needs  a  detailed  analysis  that  should
e  the  subject  of  future  works  because  adherence  to  some
sychoactive  drugs  may  not  be  relevant  for  adherence  to
ther  psychoactive  drugs.
Some  limitations  concerning  the  methodology  of  this
tudy  need  to  be  noted.  Although  the  patients’  participation
ate  was  really  high,  we  cannot  ignore  the  possible  existence
f  a  selection  bias.  Moreover,  the  patients  studied  are  from
 convenience  sample  of  consecutive  psychiatric  patients
ho  attended  outpatient  services  and,  therefore,  may  not
e  representative  of  the  entire  population  of  psychiatric
atients.  Finally,  all  questionnaires  used  were  self-reports
nd  therefore  may  be  subject  to  response  biases.
In  conclusion,  the  present  study  advances  evidence
or  the  predictive  validity  of  the  Spanish  version  of  the
idorkiewicz  instrument  for  assessing  treatment  adherence
or  each  individual  drug  taken  by  a  psychiatric  patient,  pro-
iding  relevant  information  about  medicine-taking  behaviors
ith  a  new  ‘‘drug  by  drug’’  perspective.cknowledgements
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erties of the eight-item Morisky M
(MMAS-8) in a psychiatric outpat
Journal of Clinical and Health 
http://dx.doi.org/10.1016/j.ijchp.
De las Cuevas, C., Peñate, W.,  
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